**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 67641

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Cohort Study***

**Clinical stages of recurrent hepatocellular carcinoma: a retrospective cohort study**

Yao SY *et al.* clinical stages of recurrent HCC

Si-Yang Yao, Bin Liang, Yuan-Yuan Chen, Yun-Tian Tang, Xiao-Feng Dong, Tian-Qi Liu

**Si-Yang Yao, Bin Liang, Yuan-Yuan Chen, Yun-Tian Tang, Xiao-Feng Dong, Tian-Qi Liu,** Department of Hepatobiliary-Pancreatic-Splenic Surgery, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, Guangxi Zhuang Autonomous Region, China

**Author contributions:** Liu TQ proposed the study; Yao SY and Liang B performed the research and wrote the first draft; Chen YY, Tang YT, and Dong XF collected and analyzed the data; all authors contributed to the design and interpretation of the study; and Liu TQ is the guarantor.

**Supported by** Self-financed Research Program of Health and Family Planning Commission of Guangxi Zhuang Autonomous Region, No. Z20180722.

**Corresponding author: Tian-Qi Liu, PhD, Chief Doctor,** Department of Hepatobiliary- Pancreatic-Splenic Surgery, The People’s Hospital of Guangxi Zhuang Autonomous Region, No. 6 Taoyuan Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. gxljrqt@163.com

**Received:** May 16, 2021

**Revised:** June 28, 2021

**Accepted:** August 3, 2021

**Published online:** September 26, 2021

**Abstract**

BACKGROUND

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and has relatively high recurrence rates. few studies have been published on the clinical stages of recurrent HCC.

AIM

To assess the applicability of the Barcelona Clinic Liver Cancer (BCLC) staging for recurrent HCC and the need to establish clinical stage criteria for recurrent HCC.

METHODS

The clinicopathological data of 81 patients with recurrent HCC who were admitted to the Hospital of Guangxi Zhuang Autonomous Region from January 2013 to December 2017 were collected. The patients were divided into three groups according to the BCLC staging system as follows: (1) group A with BCLC stage A, 51 patients; (2) Group B with BCLC stage B, 14 patients; and (3) Group C with BCLC stage C, 16 patients. The median time to tumor recurrence and the median overall survival were compared.

RESULTS

The median time to tumor recurrence in groups A, B, and C was 16 ± 1.5 mo, 10 ± 2.8 mo, and 6 ± 0.5 mo, respectively, with a statistically significant difference among them (*χ*2 = 70.144, *P* < 0.05); no statistically significant difference was noted between group A and group B (*χ*2 = 2.659, *P* > 0.05), although there were statistically significant differences between group A and group C and between group B and group C (*χ*2 = 62.110, and 19.972, *P* < 0.05). The median overall survival in groups A, B, and C were 42 ± 5.1 mo, 22 ± 3.1 mo, and 13 ± 1.8 mo, respectively, with a statistically significant difference among them (*χ*2 = 38.949, *P* < 0.05); there were statistically significant differences between group A and group B, group A and group C, and group B and group C (*χ*2 = 9.577, 37.172, and 7.183, respectively; *P* < 0.05).

CONCLUSION

There are different prognoses in recurrent HCC patients according to the BCLC staging. Therefore, BCLC staging is applicable to recurrent HCC and it is essential to formulate clinical stage criteria for recurrent HCC.

**Key Words:** Clinical stages; Recurrent hepatocellular carcinoma; Barcelona Clinic Liver Cancer staging system

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Yao SY, Liang B, Chen YY, Tang YT, Dong XF, Liu TQ. Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study. *World J Clin Cases* 2021; 9(27): 8020-8026

**URL:** https://www.wjgnet.com/2307-8960/full/v9/i27/8020.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v9.i27.8020

**Core Tip:** We analyzed the clinical and pathological data of 81 patients who developed recurrent hepatocellular carcinoma (HCC), with an aim to evaluate the applicability of the Barcelona Clinic Liver Cancer (BCLC) staging system for recurrent HCC. Our results indicate that BCLC staging is applicable to recurrent HCC and it is essential to formulate clinical stage criteria for recurrent HCC.

**INTRODUCTION**

In 2012, there were 782500 patients with newly diagnosed hepatocellular carcinoma (HCC) (ranked 6th worldwide) and 745500 patients who died (ranked 2nd worldwide)[1]. The radical treatment methods for HCC include liver transplantation, surgical resection (SR), and radiofrequency ablation (RFA). Numerous studies have shown that although many patients receive curative treatment, tumor recurrence is quite common. For very early stage HCC patients, the 5-year disease-free survival (DFS) rates are 40.7% for SR and 29.3% for radiofrequency ablation. For early stage HCC patients, the 5-year DFS rates are 50.8% for SR and 14.1% for radiofrequency ablation[2]. However, even in patients who undergo liver transplantation, the tumor recurrence rate is up to 15%–20%[3]. Therefore, how to manage recurrent HCC is important in improving overall survival. To date, there have not been criteria of clinical stages for recurrent HCC. The Barcelona Clinic Liver Cancer (BCLC) staging system is regarded as the most reasonable staging criteria for primary HCC. However, whether it is suitable for recurrent HCC remains unclear. The aim of this study was to assess the applicability of the BCLC staging for recurrent HCC and the need to establish clinical stage criteria for recurrent HCC, and analyze the factors affecting the prognosis of recurrent HCC patients.

**MATERIALS AND METHODS**

***Patients***

Three hundred and fifty-six recurrent HCC patients who received curative hepatic resection or RFA as an initial treatment at the People’s Hospital of Guangxi Zhuang Autonomous Region between January 2013 and December 2017 were considered candidates for this study. The inclusion criteria were as follows: (1) Pathological diagnosis of HCC; (2) No other malignant tumors or pregnancy-related disease, which may influence survival; (3) BCLC stage A, B, or C; (4) Child-pugh level A or B; and (5) Complete clinicopathological data. Finally, 81 patients met these criteria and were enrolled. This study did not require approval from the institutional ethics committee or informed consent, and complied with the principles of the Declaration of Helsinki.

The patients were stratified into three groups based on BCLC criteria: A (performance status score = 1, single tumor or multiple tumors with a maximum diameter ≤ 30mm and tumor number ≤ 3), B (tumor number > 3 or multiple tumors with a maximum diameter > 30 mm), and C (radiological evidence of vascular invasion or extrahepatic metastasis).

***Follow-up and definition of recurrence***

All patients were regularly followed to identify recurrence by assessing the level of the tumor marker alpha-fetoprotein (AFP) or performing ultrasonography (US) or contrast-enhanced computed tomography (CT) every 3 mo in the first year after radical treatment and every 6 mo in the subsequent years thereafter. If recurrence was suspected, contrast-enhanced CT, contrast-enhanced US (CEUS), or contrast-enhanced magnetic resonance imaging (MRI) was performed to confirm the diagnosis. Recurrence was defined as: (1) histopathological confirmation; and (2) Two or more imaging diagnoses of liver cancer.

***Data collection***

Clinical and pathological characteristics, including age, gender, AFP, HbsAg, HBV-DNA, tumor location, liver cirrhosis, tumor cell differentiation, treatment modalities, time to recurrence from last treatment, number of recurrences, and time of survival were collected from our electronic medical records or by telephone follow-up. All the patients were given antiviral treatment once they have positive HBV-DNA according to the guidelines of prevention and treatment for chronic hepatitis B (2010 version, China)[4].

***Statistical analysis***

Continuous variables were assessed for normality and are expressed as the mean ± SD, and comparisons among groups were evaluated by ANOVA. Categorical variables were compared by Chi-square test or Fisher’s exact test with small expected frequencies (< 5). Survival time is presented in months. Survival curves and recurrence curves for recurrent HCC patients were analyzed by the Kaplan-Meier method and the differences were analyzed by the log-rank test. All statistical analyses were performed using SPSS for Windows version 19.0 and *P* values < 0.05 were considered significant.

**RESULTS**

***Baseline data comparison***

We identified 81 patients, and all of them underwent a complete follow-up. The follow-up time ranged from 2 to 65 mo, with an average follow-up time of 23 ± 15 mo. There were 72 males and 9 females, with a mean age of 53 years (range, 25–82 years). There were 51 cases in group A, 14 cases in group B, and 16 cases in group C. No significant differences were detected among the three groups with respect to age, gender, AFP, HbsAg, HBV-DNA, tumor location, liver cirrhosis, tumor cell differentiation, treatment modalities, time to recurrence from last treatment, or number of recurrences (Table 1).

***Recurrence and survival***

The median time to tumor recurrence for group A, group B, and group C was 16 ± 1.5 mo, 10 ± 2.8 mo, and 6 ± 0.5 mo, respectively, with a statistically significant difference among them (*χ*2 = 70.144, *P* < 0.05); no statistically significant difference was noted between group A and group B (*χ*2 = 2.659, *P* > 0.05), but there were statistically significant differences between group A and group C, and group B and group C (*χ*2 = 62.110 and 19.972, respectively, *P* < 0.05) (Figure 1).

The median time of overall survival for group A, group B, and group C was 42 ± 5.1 mo, 22 ± 3.1 mo, and 13 ± 1.8 mo, respectively, with a statistically significant difference among them (*χ*2 = 38.949, *P* < 0.05); there were statistically significant differences between group A and group B, group A and group C, and group B and group C (*χ*2 = 9.577, 37.172, and 7.183, respectively, *P* < 0.05) (Figure 2)

**DISCUSSION**

Since the BCLC staging system was put forward in 1999, it has been confirmed by a large number of clinical studies and is considered to be the most reasonable liver cancer staging criteria by combining tumor status, liver function, and treatment strategies.

Recurrence is one of the most important reasons why the prognosis of HCC is difficult to improve. At present, there have been guidelines for primary liver cancer, but for recurrent liver cancer, there is still much controversy[5,6]. Some researchers consider that the treatment for recurrent HCC can refer to that for primary HCC, including repeat hepatectomy, liver transplantation, local ablation, interventional therapy, radiotherapy, and systemic therapy[7,8]. Although SR is the best treatment option for patients with HCC, the 3-year recurrence rate is still as high as 50%-70%[9]. The treatment modalities for recurrent HCC include liver transplantation, SR, RFA, transcatheter arterial chemoembolization, and targeted therapy. Several studies show that 10%-30% of recurrent HCC patients underwent repeated SR, with a 5-year survival rate of 22%-83%, which is similar to that with first time hepatectomy[10,11]. Sun *et al*[12] found that in small recurrent HCC after SR, RFA achieved a similar overall survival and disease-free survival compared with repeated SR and resulted in a shorter hospital stay. Another meta-analysis showed contrary results, reporting that the 3-year survival after repeated SR is higher than that after RFA[13]. To date, how to manage recurrent HCC patients remains confusing, and there has not been a unanimous opinion about the treatment of recurrent HCC. Therefore, it is essential to establish clinical stages for recurrent HCC, which can provide more precise and individual treatment plans for recurrent HCC patients.

Is the Barcelona Clinic Liver Cancer (BCLC) staging system applicable to recurrent HCC? In our study, the median time to tumor recurrence for group A, group B, and group C was 16 ± 1.5 mo, 10 ± 2.8 mo, and 6 ± 0.5 mo, respectively, with a statistically significant difference among them (*P* < 0.05); there was no statistically significant difference between group A and group B (*χ*2 = 2.659, *P* > 0.05), but there were statistically significant differences between group A and group C, and group B and group C (*P* < 0.05). Meanwhile, the median time of overall survival for group A, group B, and group C was 42 ± 5.1 mo, 22 ± 3.1 mo, and 13 ± 1.8 mo, respectively, with a statistically significant difference among them (*P* < 0.05); there were statistically significant differences between group A and group B, group A and group C, and group B and group C (*P* < 0.05). Our study showed the BCLC staging system is applicable to recurrent HCC, and there are different prognoses in recurrent HCC patients with different stages classified by BCLC, which is just similar to that for primary HCC. It is essential to formulate the standard of clinical stages for recurrent HCC, which would contribute to the development of more precise and individual treatment plans for recurrent HCC patients, and, improve the therapeutic efficacy for recurrent HCC. Our study showed as well that the regular examination and follow-up are important because they can increase the rate of early diagnosis and treatment for recurrent HCC. Further research is needed to provide a more exact staging basis for recurrent HCC.

The limitations of our study included its non-prospective nature and small cohort size, which would lead to recall bias. Therefore, there is clearly a need for larger sample, prospective, multicenter clinical trials to confirm our conclusion in the future, and it is essential to formulate a better clinical staging system for recurrent HCC.

**CONCLUSION**

There are different prognoses in recurrent HCC patients with different stages classified by BCLC, which is just similar to that for primary HCC. BCLC staging system is applicable to recurrent HCC, but not precisely enough. It is essential to formulate the standard of clinical stages for recurrent HCC, which would contribute to the development of more precise and individual treatment plans for recurrent HCC patients, and, improve the therapeutic efficacy for recurrent HCC.

**ARTICLE HIGHLIGHTS**

***Research background***

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and has relatively high recurrence rates. At present, there has not been a unanimous opinion for the treatment of recurrent HCC, and clinical stages of recurrent HCC remain controversial.

***Research motivation***

This study showed that the Barcelona Clinic Liver Cancer (BCLC) staging system is applicable to recurrent HCC, and it is essential to formulate the standard of clinical stages for recurrent HCC, which would contribute to the development of more precise and individual treatment plans for recurrent HCC patients.

***Research objectives***

The aim of this study was to assess the applicability of the BCLC staging for recurrent HCC and the need to establish clinical stage criteria for recurrent HCC.

***Research methods***

The clinicopathological data of 81 patients with recurrent HCC were collected. The patients were divided into three groups according to the BCLC staging system as follows: (1) group A with BCLC stage A, 51 patients; (2) Group B with BCLC stage B, 14 patients; and (3) Group C with BCLC stage C, 16 patients. The median time to tumor recurrence time and the median overall survival were compared.

***Research results***

The median time to tumor recurrence in groups A, B, and C was 16 ± 1.5 mo, 10 ± 2.8 mo, and 6 ± 0.5 mo, respectively, with a statistically significant difference among them; no statistically significant difference was noted between group A and group B, although there were statistically significant differences between group A and group C and between group B and group C. The median overall survival time in groups A, B, and C was 42 ± 5.1 mo, 22 ± 3.1 mo, and 13 ± 1.8 mo, respectively, with a statistically significant difference among them; there were statistically significant differences between group A and group B, group A and group C, and group B and group C.

***Research conclusions***

There are different prognoses in recurrent HCC patients according to the BCLC. Therefore, BCLC staging is applicable to recurrent HCC and it is essential to formulate clinical stage criteria for recurrent HCC.

***Research perspectives***

Recurrent HCC patients with different clinical stages have different prognoses, and it is essential to formulate more precise clinical stage criteria for recurrent HCC.

**REFERENCES**

1 **Torre LA**, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015; **65**: 87-108 [PMID: 25651787 DOI: 10.3322/caac.21262]

2 **Wang JH**, Wang CC, Hung CH, Chen CL, Lu SN. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. *J Hepatol* 2012; **56**: 412-418 [PMID: 21756858 DOI: 10.1016/j.jhep.2011.05.020]

3 **Welker MW**, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge. *Transpl Int* 2013; **26**: 109-118 [PMID: 22994652 DOI: 10.1111/j.1432-2277.2012.01562.x]

4 **Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association**. [The guideline of prevention and treatment for chronic hepatitis B (2010 version)]. *Zhonghua Gan Zang Bing Za Zhi* 2011; **19**: 13-24 [PMID: 21272453 DOI: 10.3760/cma.j.issn.1007-3418.2011.01.007]

5 **Saraswat VA**, Pandey G, Shetty S. Treatment algorithms for managing hepatocellular carcinoma. *J Clin Exp Hepatol* 2014; **4**: S80-S89 [PMID: 25755616 DOI: 10.1016/j.jceh.2014.05.004]

6 **Zhou J**, Sun HC, Wang Z, Cong WM, Wang JH, Zeng MS, Yang JM, Bie P, Liu LX, Wen TF, Han GH, Wang MQ, Liu RB, Lu LG, Ren ZG, Chen MS, Zeng ZC, Liang P, Liang CH, Chen M, Yan FH, Wang WP, Ji Y, Cheng WW, Dai CL, Jia WD, Li YM, Li YX, Liang J, Liu TS, Lv GY, Mao YL, Ren WX, Shi HC, Wang WT, Wang XY, Xing BC, Xu JM, Yang JY, Yang YF, Ye SL, Yin ZY, Zhang BH, Zhang SJ, Zhou WP, Zhu JY, Liu R, Shi YH, Xiao YS, Dai Z, Teng GJ, Cai JQ, Wang WL, Dong JH, Li Q, Shen F, Qin SK, Fan J. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). *Liver Cancer* 2018; **7**: 235-260 [PMID: 30319983 DOI: 10.1159/000488035]

7 **Erridge S**, Sodergren MH. The Chengdu system for recurrent hepatocellular carcinoma: A step in the right direction. *Hepatobiliary Surg Nutr* 2019; **8**: 298-300 [PMID: 31245419 DOI: 10.21037/hbsn.2019.01.17]

8 **Wen T**, Jin C, Facciorusso A, Donadon M, Han HS, Mao Y, Dai C, Cheng S, Zhang B, Peng B, Du S, Jia C, Xu F, Shi J, Sun J, Zhu P, Nara S, Millis JM; MDT of West China Hospital\*. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. *Hepatobiliary Surg Nutr* 2018; **7**: 353-371 [PMID: 30498711 DOI: 10.21037/hbsn.2018.08.01]

9 **Torzilli G**, Donadon M, Cimino M. Are Tumor Exposure and Anatomical Resection Antithetical during Surgery for Hepatocellular Carcinoma? A Critical Review. *Liver Cancer* 2012; **1**: 177-182 [PMID: 24159582 DOI: 10.1159/000343831]

10 **Chan DL**, Morris DL, Chua TC. Clinical efficacy and predictors of outcomes of repeat hepatectomy for recurrent hepatocellular carcinoma - a systematic review. *Surg Oncol* 2013; **22**: e23-e30 [PMID: 23535302 DOI: 10.1016/j.suronc.2013.02.009]

11 **Cabibbo G**, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. *Hepatology* 2010; **51**: 1274-1283 [PMID: 20112254 DOI: 10.1002/hep.23485]

12 **Sun WC**, Chen IS, Liang HL, Tsai CC, Chen YC, Wang BW, Lin HS, Chan HH, Hsu PI, Tsai WL, Cheng JS. Comparison of repeated surgical resection and radiofrequency ablation for small recurrent hepatocellular carcinoma after primary resection. *Oncotarget* 2017; **8**: 104571-104581 [PMID: 29262662 DOI: 10.18632/oncotarget.21604]

13 **Jiang H**, Wan SY, Hou H, Zhou LB, Yu ZF, Geng XP. A meta-analysis of the efficacy of rehepatectomy and radiofrequency ablation for recurrence liver cancer. *Zhonghua Putong Waike Zazhi* 2015; **30**: 146-149 [DOI: 10.3760/cma.j.issn.1007-631X.2015.02.018]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by The People’s Hospital of Guangxi Zhuang Autonomous Region Institutional Review Board (Approval No. KY-LW-2019-4).

**Informed consent statement:** Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

**Conflict-of-interest statement:** All the authors have no conflict of interest related to the manuscript.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement, and the manuscript was prepared and revised according to the STROBE Statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** May 16, 2021

**First decision:** June 15, 2021

**Article in press:** August 3, 2021

**Specialty type:** Surgery

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Hann HW **S-Editor:** Ma YJ **L-Editor:** Wang TQ **P-Editor:** Yuan YY

**Figure Legends**



**Figure 1 Recurrence curve of recurrent hepatocellular carcinoma.**



**Figure 2 Overall survival curve of recurrent hepatocellular carcinoma.**

**Table 1 Comparison of clinicopathological features among the three groups**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable** | **Group A (*n* = 51)** | **Group B (*n* = 14)** | **Group C (*n* = 16)** | ***χ*2 value/*F* value** | ***P* value** |
| Gender (male/female) | 44/7 | 13/1 | 15/1 | 0.622 | 0.784 |
| Age (yr) | 54 ± 13 (33-82) | 48 ± 11 (25-67) | 52 ± 10 (39-67) | 1.028 | 0.461 |
| AFP (μg/L) | 353.5 ± 104.5 (143.5-563.4) | 121.9 ± 47.5 (19.2-224.6) | 326.9 ± 90.6 (133.8-519.9) | 0.769 | 0.467 |
| HBsAg (negative/positive) | 4/47 | 2/12 | 1/15 | 0.968 | 0.728 |
| HBV-DNA (negative/positive) | 39/12 | 7/7 | 8/8 | 5.956 | 0.051 |
| Tumor location (left lobe/right lobe/both lobe ) | 9/37/5 | 0/10/4 | 2/9/5 | 7.459 | 0.089 |
| Liver cirrhosis (negative/positive) | 23/28 | 8/6 | 6/10 | 1.180 | 0.554 |
| Tumor cell differentiation (well/moderate/poor) | 9/32/10 | 4/8/2 | 2/10/4 | 1.655 | 0.832 |
| Treatment modality (RFA/RFA + PEI/TACE/LR) | 21/20/1/9 | 4/6/1/3 | 7/2/4/3 | 10.933 | 0.064 |
| Time to recurrence from last treatment (mo) | 26.6 ± 3.9 (18.6-34.5) | 22.6 ± 4.1 (13.7-31.6) | 17.3 ± 5.3 (5.9-28.5) | 0.856 | 0.429 |
| Number of recurrences (first/second) | 43/8 | 10/4 | 11/5 | 2.632 | 0.285 |

Data are expressed as the mean ± SD. AFP: Alpha-fetal protein; HBsAg: Hepatitis B surface antigen; HBV-DNA: Hepatitis B virus deoxyribonucleic acid; RFA: Radiofrequency ablation; PEI: Percutaneous ethanol injection therapy; TACE: Transarterial chemoembolization; LR: Liver resection.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**